Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan

American Heart Journal

Volumn 139, Issue 4, 2000, Pages 587-595

  Moe, Gordon W ^a   Rouleau, Jean L ^b   Charbonneau, Lynne ^b   Proulx, Guy ^b   Arnold, J Malcolm O ^b   Hall, Christian ^b   De Champlain, Jacques ^b   Barr, Aiala ^b   Sirois, Pierre ^b   Packer, Milton ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; FLOSEQUINAN; NORADRENALIN; PLACEBO; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 0034033977     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90035-8     Document Type: Article

References (34)

1. 1. Kessler PD, Packer M. Hemodynamic effects of BTS 49465, a long-acting systemic vasodilator drug, in patients with severe congestive heart failure. Am Heart J 1987;113:137-43.
2. 2. Elborn JS, Stanford CF, Nicholls DP. Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Br Heart J 1989;61:331-5.
3. 3. Haas GJ, Binkley PE, Leier CV. Chronic vasodilator therapy with flosequinan in congestive heart failure. Clin Cardiol 1990;13:414-20.
4. 4. Corin WJ, Monrad S, Strom JA, et al. Flosequinan: a vasodilator with positive inotropic activity. Am Heart J 1991;121:537-40.
5. 5. Burstein S, Semigran MJ, Dec GW Jr, et al. Positive inotropic and lusitropic effects of flosequinan in patients with heart failure. J Am Coll Cardiol 1992;20:822-9.
6. 6. Kessler PD, Packer M, Medina N, et al. Cumulative hemodynamic response to short term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure. J Cardiovasc Pharmacol 1988;12:6-11.
7. 7. Cowley AJJ, Wynn RD, Stainer K, et al. Flosequinan in heart failure: acute hemodynamic and long term symptomatic benefits. BMJ 1988; 297:170-3.
8. 8. Cavero PG, De Marco T, Kwasman M, et al. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. J Am Coll Cardiol 1992; 20:1542-8.
9. 9. Gottlieb SS, Kikin ML, Penn J, et al. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 1993;22:963-7.
10. 10. Packer M, Narahara KA, Elkayam U, et al. Double blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. J Am Coll Cardiol 1993;22:65-72.
11. 11. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretics, digoxin, and an angiotensin converting enzyme inhibitor? Circulation 1993;88:492-501.
12. 12. Packer M, Lee WH, Kessler PD, et al. Role of neurohormonal mechanisms in determining survival in patients with severe heart failure. Circulation 1987;75:IV80-IV92.
13. 13. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988,77:721-30.
14. 14. Benedict CR, Johnstone ED, Weiner DH, et al for the SOLVD investigators. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the registry of studies of left ventricular dysfunction. J Am Coll Cardiol 1994;23:1410-20.
15. 15. Francis GS, Benedict C, Johnstone DE, et al for the SOLVD investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
16. 16. Cohn JN, Levine B, Olivari M, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
17. 17. Gottlieb SS, Kukin ML, Ahern D, et al. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
18. 18. Swedberg K, Eneroth P, Kjekshus K, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure. Circulation 1990;82:1730-6.
19. 19. Waagstein F, Bristow M, Swedberg K, et al for the Metoprolol in Dilated Cardiomyopathy (MDC) trial study group. Lancet 1993; 342:1441-6.
20. 20. Packer M, Bristow M, Cohen J, et al. The effect of carvedilol on survival and hospitalization for cardiovascular complications in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
21. 21. CIBIS-II investigators and committee. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
22. 22. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
23. 23. The SOLVD investigators. Effect of enalapril on survival in patients with reduced ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
24. 24. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
25. 25. Kettunen RVJ, Leppaluoto J, Jounela A, et al. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction. Am Heart J 1994;127:1449-55.
26. 26. Lerman A, Gibbons RJ, Rodeheffer RJ, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left ventricular dysfunction. Lancet 1993;341:1105-9.
27. 27. Hall C, Rouleau JJL, Moye L, et al. N-terminal proatrial natriuretic factor. An independent predictor of long term prognosis after myocardial infarction. Circulation 1994;89:1934-42.
28. 28. Hall C, Kjekshus J, Eneroth P, et al. Plasma concentration of N-terminal proatrial natriuretic factor ANF (1-98) is related to prognosis in severe heart failure. Clin Cardiol 1994;17:191-5.
29. 29. Peuler JD, Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 1977;21:625-36.
30. 30. Binkley PF, Nunziata E, Cody RJ. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence long-term vasodilator administration. Am Heart J 1994;128:1147-56.
31. 31. Rector TS, Olivari MT, Levine B, et al. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J 1987;114:148-52.
32. 32. Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-7.
33. 33. Reit E. Interaction of angiotensin with the autonomic nervous system. Fed Proc 1972;31:1331-64.
34. 34. Berecek KH, Webb RL, Brody MJ. Evidence for a central role for vasopressin in cardiovascular regulation. Am J Physiol 1983;13: H852-H859.